Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

2023-509283-14-00 Protocol BNT116-01 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 25 Apr 2022 · Status Ongoing, recruiting · 4 EU/EEA countries · 18 sites · Protocol BNT116-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 313
Countries 4
Sites 18

Advanced non-small cell lung cancer

Key facts

Sponsor
BioNTech SE
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
25 Apr 2022 → ongoing
Decision date (initial)
2024-02-02
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-509283-14-00
EudraCT number
2021-004739-94
ClinicalTrials.gov
NCT05142189

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced non-small cell lung cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

BioNTech SE

Sponsor organisation
BioNTech SE
Address
An Der Goldgrube 12, Oberstadt Oberstadt
City
Mainz
Postcode
55131
Country
Germany

Scientific contact point

Organisation
BioNTech SE
Contact name
Clinical Trial Information Desk

Public contact point

Organisation
BioNTech SE
Contact name
Clinical Trial Information Desk

Locations

4 EU/EEA countries · 18 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 27 4
Hungary Ongoing, recruiting 34 3
Poland Ongoing, recruiting 31 3
Spain Ongoing, recruiting 64 8
Rest of world
United States, United Kingdom, Turkey, Australia
157

Investigational sites

Germany

4 sites · Ongoing, recruiting
University Medical Center Hamburg-Eppendorf
II. Medizinische Klinik und Poliklinik, Martinistrasse 52, Eppendorf, Hamburg
University Hospital Cologne AöR
Klinik I für Innere Medizin, Kerpener Strasse 62, Lindenthal, Cologne
Krankenhaus Nordwest GmbH
Klinik für Onkologie und Hämatologie, Steinbacher Hohl 2-26, Praunheim, Frankfurt Am Main
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
III. Med. Klinik, Langenbeckstrasse 1, Oberstadt, Mainz

Hungary

3 sites · Ongoing, recruiting
Clinexpert Kft.
Fázis 1 Vizsgálóhely, Dozsa Gyorgy Utca 15, 3200, Gyongyos
Orszagos Onkologiai Intezet
“B” Belgyógyászat-Onkológiai és Klinikai Farmakológiai Osztály, Rath Gyorgy Utca 7-9, Kerulet, Budapest XII
Semmelweis University
Belgyógyászati és Onkológiai Klinika (Klinikai Farmakológiai Részleg, Koranyi Sandor Utca 2/a, Kerulet, Budapest VIII

Poland

3 sites · Ongoing, recruiting
Uniwersyteckie Centrum Kliniczne
Ośrodek Badań Klinicznych Wczesnych Faz, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk
Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie
Oddział Onkologii i pododdziałem chemioterapii, Ul. Jagiellonska Nr 78, 10-357, Olsztyn
Med Polonia Sp. z o.o.
NA/ND, Obornicka 262, 60-693, Poznan

Spain

8 sites · Ongoing, recruiting
Hospital Universitario Y Politecnico La Fe
Oncology, Avenida De Fernando Abril Martorell 106, 46026, Valencia
Hospital Universitario Virgen De La Macarena
Oncology, Avenida Del Doctor Fedriani 3, 41009, Sevilla
MD Anderson Cancer Center
Oncology, Calle De Arturo Soria Nº 270, 28033, Madrid
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Hospital Universitari Vall D Hebron
Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Germans Trias I Pujol
Oncology, Carretera Canyet 1a Planta, 08916, Badalona
Complexo Hospitalario Universitario De Santiago
Oncology, Calle Choupana Da S/n, 15706, Santiago De Compostela

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2022-11-09 2022-11-15
Hungary 2022-04-25 2022-06-17
Poland 2023-03-08 2023-08-30
Spain 2023-03-23 2023-04-19

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-19 Germany Acceptable
2024-01-31
2024-02-01
2 SUBSTANTIAL MODIFICATION SM-1 2024-05-16 Germany Acceptable
2024-07-22
2024-07-24
3 SUBSTANTIAL MODIFICATION SM-2 2024-12-18 Germany Acceptable
2025-04-14
2025-04-16
4 SUBSTANTIAL MODIFICATION SM-3 2025-08-12 Germany Acceptable
2025-11-17
2025-11-18
5 SUBSTANTIAL MODIFICATION SM-4 2025-12-18 Germany Acceptable
2026-03-09
2026-03-09
6 SUBSTANTIAL MODIFICATION SM-6 2026-03-19 Acceptable 2026-04-02